Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

NCT02028884 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromyelitis Optica (NMO)
NMO Spectrum Disorder (NMOSD)

Interventions

DRUG: Satralizumab
DRUG: Placebo
DRUG: Baseline Treatment

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]